The study of the specific pharmacological activity of Dermabin on the model of the experimental contact dermatitis in rats


  • V. L. Karbovskyy LLC “Pharmaceutical Plant “Biofarma”, Ukraine
  • I. A. Shevchuk LLC “Pharmaceutical Plant “Biofarma”, Ukraine
  • O. V. Kurkina LLC “Pharmaceutical Plant “Biofarma”, Ukraine
  • T. Ye. Makovska Main Military Medical Hospital, Ukraine



psoriasis, contact dermatitis, DERMABIN, betamethasone dipropionate, salicylic acid


In spite of a great number of the existing drugs and methods, as well as introduction of the new ones, the problem of improving the treatment of patients with psoriasis and psoriatic arthritis is still one of the most burning and topical in modern dermatology. In case of such disorders, glucocorticoids are the most effective if combined with keratolytics – the effective agents facilitating the drug penetration directly to the affected area. The aim of the work was to study the specific pharmacological activity of Dermabin medicine on the model of contact dermatitis in rats compared to Diprosalik. In order to reproduce this pathology rats were applied 2,4-dinitrochlorobenzene in the form of 5% ethanol–acetone solution twice a day for 4 days. In 4 days after the first application the area affected by contact dermatitis (CD) was covered with Dermabin or the reference medicine Diprosalic for 14 days. The severity of psoriasis developed was assessed daily based on the change of the skin covering indices: the skin fold thickness and the severity of skin manifestation. It was registered that in animals with the test and reference medicines applied the hemorrhagic crusting began exfoliating on the 4th day of the treatment, which was twice faster than in rats of the control group, and the skin fold thickness significantly decreased. On the 7th and 10th days of the treatment the progressive improvement of the CD affected area was observed in these animals. On the 14th day all rats receiving the active treatment showed significant restoration of their appearance, and the ESR index decreased almost to the level observed in intact animals. At the same time the severity of leucocytosis also reduced. Therefore, the results obtained indicate the marked anti-inflammatory activity of Dermabin medicine in rats with the experimental model of contact dermatitis.


Булига Л.О., Бутко Я.О., Іванцик Л.Б. // Фармакол. та лікарська токсикол. – 2012. – №6 (31) .– С. 18-22.

Залкан П.М., Иевлева Е.А. Влияние синтетических моющих средств на реактивность кожи морских свинок / В кн.: Актуальные вопросы профессиональной дерматологии. – М., 1965. – С. 106-112.

Лабораторные исследования в клинике / Под ред. В.В.Меньшикова – М.: Медицина, 1987. – 365 с.

Псориаз. Клинические рекомендации / Под ред. А.А.Кубановой. – М.: ДЭКС-Пресс, 2008. – 56 с.

Реброва О.Ю. Статистический анализ медицинских данных. Применение пакета прикладных программ STATISTICA. – 3-е изд. – М.: МедиаСфера, 2006. – 312 с.

Руководство по проведению доклинических исследований лекарственных средств. Ч. I. – М.: Гриф и К, 2012. – 944 с.

Стефанов О., Бухтіарова Т., Коваленко В. та ін. Настанова СТ-Н МОЗУ 42-6.0:2008. Лікарські засоби. Належна лабораторна практика (видання офіційне). – К. : Моріон, 2009. – С. 37-68.

Campbell J.J., Haraldsen G., Pan J. et al. // Nature. – 1999. – Vol. 400. – P. 776-780.

Chiricozzi A. Pathogenic // Actas Dermosifiliogr. – 2014. – Vol. 105, Suppl. 1. – P. 9-20.

Dubertret L. // Med. Sci. – 2006. – Vol. 22. – P.164-171.

Eberle F.C., Brück J., Holstein J. et al. // F1000Res. – 2016. – Apr 28. – P. 5.

European convention for the protection of vertebrate animals used for experimental and other scientific purpose: Council of Europe 18.03.1986. – Strasbourg, 1986. – 52 p.

Gudjonsson J.E., Elder J.T. // Clin. Dermatol. – 2007. – Vol. 5. – P. 535-546.

Homey B., Alenius H., Müller A. et al. // Nat. Med. – 2002. – Vol. 8 (2). – P. 157-165.

Homey B. // Curr. Drug Targets Inflamm. Allergy. – 2004. – Vol. 3. – P. 169-174.

Koo J., Cuffie C.A., Tanner D.J. et al. // Clin. Ther. – 1998. – Vol. 20. – P. 283-291.

Lowes M.A., Suárez-Fariñas M., Krueger J.G. // Annu Rev. Immunol. – 2014. – Vol. 32. – P. 227-255.

Mirshafiey A., Simhag A., El Rouby N.M., Azizi G. // Int. J. Dermatol. – 2015. – Vol. 54 (8). – P. 880-888.

Pathirana D., Ormerod A.D., Saiag P. et al. // J. Eur. Acad. Dermatol. Venerol. – 2010. – Vol. 24 (1). – P. 117-118.

Rhen T., Cidlowski J.A. // N. Engl. J. Med. – 2006. – Vol. 35 (16). – P. 1711-1723.

Schön M.P., Ruzicka T. // Nat. Immunol. – 2001. – Vol. 2. – P. 91.

Vegfors J., Ekman A.K., Stoll S.W. et al. // Br. J. Dermatol. – 2016. – May 7. [Epub ahead of print].






Pre-clinical studies of new drugs